Status:
COMPLETED
Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome
Lead Sponsor:
King Chulalongkorn Memorial Hospital
Conditions:
Mycobacterium Abscessus Infection
Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies
Eligibility:
All Genders
18+ years
Brief Summary
The treatment outcome of Mycobacterium abscessus infection in acquired interferon-gamma autoantibody syndrome has not been well studied. Investigators will perform a retrospective and prospective coho...
Detailed Description
The single center, retrospective and prospective cohort study including the patients, aged 18 years and over, with acquired interferon-gamma autoantibody syndrome or chronic lung disease diagnosed wit...
Eligibility Criteria
Inclusion
- Aged 18 years or over
- Diagnosed with Mycobacterium abscessus pulmonary disease in chronic lung disease or Mycobacterium abscessus infection in acquired interferon-gamma autoantibody syndrome
- Receive appropriate treatment
Exclusion
- Follow up time less than one year after the start of appropriate treatment
- Very incomplete medical record that the subject's history cannot be reviewed
- Appropriate treatment duration less than one year at the study completion
Key Trial Info
Start Date :
June 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05354583
Start Date
June 15 2022
End Date
September 30 2023
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Chulalongkorn Memorial Hospital
Pathum Wan, Bangkok, Thailand, 10330